BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

NASDAQ:BIOA • US09077V1008

22.25 USD
+0.11 (+0.5%)
Last: Feb 26, 2026, 11:59 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BIOA scores 3 out of 10 in our fundamental rating. BIOA was compared to 192 industry peers in the Pharmaceuticals industry. BIOA has a great financial health rating, but its profitability evaluates not so good. BIOA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BIOA had negative earnings in the past year.
  • BIOA had a negative operating cash flow in the past year.
BIOA Yearly Net Income VS EBIT VS OCF VS FCFBIOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • BIOA's Return On Assets of -24.84% is in line compared to the rest of the industry. BIOA outperforms 58.85% of its industry peers.
  • BIOA has a Return On Equity of -27.32%. This is in the better half of the industry: BIOA outperforms 65.10% of its industry peers.
Industry RankSector Rank
ROA -24.84%
ROE -27.32%
ROIC N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOA Yearly ROA, ROE, ROICBIOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BIOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOA Yearly Profit, Operating, Gross MarginsBIOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • BIOA has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, BIOA has an improved debt to assets ratio.
BIOA Yearly Shares OutstandingBIOA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
BIOA Yearly Total Debt VS Total AssetsBIOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 18.76 indicates that BIOA is not in any danger for bankruptcy at the moment.
  • BIOA has a Altman-Z score of 18.76. This is amongst the best in the industry. BIOA outperforms 87.50% of its industry peers.
  • BIOA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.76
ROIC/WACCN/A
WACCN/A
BIOA Yearly LT Debt VS Equity VS FCFBIOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • BIOA has a Current Ratio of 11.87. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of BIOA (11.87) is better than 80.21% of its industry peers.
  • BIOA has a Quick Ratio of 11.87. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
  • BIOA's Quick ratio of 11.87 is amongst the best of the industry. BIOA outperforms 80.21% of its industry peers.
Industry RankSector Rank
Current Ratio 11.87
Quick Ratio 11.87
BIOA Yearly Current Assets VS Current LiabilitesBIOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for BIOA have decreased by -6.13% in the last year.
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BIOA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.69% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.53%
EPS Next 2Y28.06%
EPS Next 3Y17.6%
EPS Next 5Y8.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOA Yearly Revenue VS EstimatesBIOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2032 2033 5M 10M 15M 20M 25M
BIOA Yearly EPS VS EstimatesBIOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2029 2030 2031 2032 2033 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • BIOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOA Price Earnings VS Forward Price EarningsBIOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOA Per share dataBIOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • BIOA's earnings are expected to grow with 17.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.06%
EPS Next 3Y17.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BIOA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOAGE LABS INC

NASDAQ:BIOA (2/26/2026, 11:59:06 AM)

22.25

+0.11 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-19
Inst Owners67.3%
Inst Owner Change5.87%
Ins Owners3.64%
Ins Owner Change-11%
Market Cap928.94M
Revenue(TTM)5.92M
Net Income(TTM)-75.79M
Analysts78.18
Price Target27.8 (24.94%)
Short Float %2.28%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.16%
Min EPS beat(2)-22.35%
Max EPS beat(2)6.02%
EPS beat(4)3
Avg EPS beat(4)6%
Min EPS beat(4)-22.35%
Max EPS beat(4)33.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)201.02%
Min Revenue beat(2)94.32%
Max Revenue beat(2)307.71%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)127.08%
PT rev (3m)181.9%
EPS NQ rev (1m)2%
EPS NQ rev (3m)2%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-4.42%
Revenue NQ rev (1m)-20.01%
Revenue NQ rev (3m)-20.01%
Revenue NY rev (1m)-2.72%
Revenue NY rev (3m)48.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 156.99
P/FCF N/A
P/OCF N/A
P/B 3.35
P/tB 3.35
EV/EBITDA N/A
EPS(TTM)-3.49
EYN/A
EPS(NY)-2.96
Fwd EYN/A
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS0.14
BVpS6.65
TBVpS6.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.84%
ROE -27.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 331.41%
Cap/Sales 10.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.87
Quick Ratio 11.87
Altman-Z 18.76
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.64%
EPS Next Y71.53%
EPS Next 2Y28.06%
EPS Next 3Y17.6%
EPS Next 5Y8.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.96%
EBIT Next 3Y-16.92%
EBIT Next 5YN/A
FCF growth 1Y-38.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAGE LABS INC / BIOA FAQ

What is the ChartMill fundamental rating of BIOAGE LABS INC (BIOA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIOA.


Can you provide the valuation status for BIOAGE LABS INC?

ChartMill assigns a valuation rating of 0 / 10 to BIOAGE LABS INC (BIOA). This can be considered as Overvalued.


Can you provide the profitability details for BIOAGE LABS INC?

BIOAGE LABS INC (BIOA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BIOA stock?

The Earnings per Share (EPS) of BIOAGE LABS INC (BIOA) is expected to grow by 71.53% in the next year.